AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

2.060

-0.030-1.44%

Volume:5.89M

Turnover:12.24M

Market Cap:2.63B

PE:-14.01

High:2.130

Open:2.100

Low:2.035

Close:2.090

Loading ...

Overview Company News Filings

Mesoblast Cut to Hold From Buy by Jefferies

Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30

MT Newswires Live

US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says

MT Newswires Live

Shares vs. property: Biggest investment trends of 2024

Galloping to the top of the runners of the week podium is… icetana

The Sydney Morning Herald

Why Bellevue Gold, Mesoblast, Pilbara Minerals, and Wesfarmers shares are dropping today

Why the Mesoblast share price is diving 18% after an FDA win

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

Mesoblast Is Maintained at Overweight by Piper Sandler

U.S.-Listed Shares of Mesoblast up 44% After FDA Approves Cell Therapy for Graft-Versus-Host Disease

THOMSON REUTERS

BUZZ-Mesoblast gains on FDA nod for graft-versus-host disease cell therapy

U.S.-Listed Shares of Mesoblast Surge 49% Premarket After FDA Approves Cell Therapy for Graft-Versus-Host Disease

THOMSON REUTERS

Why Champion Iron, EBR Systems, Mesoblast, and Patriot Battery Metals shares are surging today

BUZZ-Australia's Mesoblast at 4-yr high on US FDA nod for cell therapy

Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease

Mesoblast Receives US FDA Approval for Mesenchymal Stromal Cell Therapy; Shares Hit Four-Year High

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/MSB.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.06,"timestamp":1741583520000,"preClose":2.09,"halted":0,"volume":5890076,"delay":0,"changeRate":-0.014354,"change":-0.03,"floatShares":738087712,"shares":1274447688,"eps":-0.14704555,"lyrEps":-0.14207,"pbRate":3.57,"amount":12244880,"amplitude":0.045455,"volumeRatio":0.4585138231458109,"dividePrice":0,"prevYearClose":3.1,"fiveDayClose":2.51,"twentyDayClose":3.02},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":738087712,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.142067,"volumeRatio":0.4585138231458109,"shares":1274447688,"dividePrice":0,"high":2.13,"amplitude":0.045455,"preClose":2.09,"low":2.035,"week52Low":0.325,"pbRate":"3.57","psRate":"290.53","week52High":3.37,"institutionHeld":0,"latestPrice":2.06,"eps":-0.14704297990616075,"divideRate":0,"volume":5890076,"delay":0,"ttmEps":-0.14704297990616075,"open":2.1,"prevYearClose":3.1,"prevWeekClose":2.09,"prevMonthClose":2.52,"prevQuarterClose":3.1,"fiveDayClose":2.51,"twentyDayClose":3.02,"sixtyDayClose":1.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:16,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2493759384","title":"Mesoblast Cut to Hold From Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2493759384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493759384?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:07","pubTimestamp":1734955620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MESO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2024 07:07 ET (12:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK7067","BK7508","BK7501","MESO","MSB.AU"],"gpt_icon":0},{"id":"2493505736","title":"Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2493505736","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493505736?lang=en_us&edition=fundamental","pubTime":"2024-12-23 17:05","pubTimestamp":1734944720,"startTime":"0","endTime":"0","summary":"Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2493520692","title":"US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2493520692","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493520692?lang=en_us&edition=fundamental","pubTime":"2024-12-23 11:19","pubTimestamp":1734923952,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration's approval of a mesenchymal stromal cell (MSC) therapy bodes well for Cynata Therapeutics (ASX:CYP), Euroz Hartleys said in a Dec. 19 note.Cynata Therapeutics focus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7067","BK7501","BK4575","BK4150","BK7508","CYP.AU","MSB.AU","MSC","LENZ"],"gpt_icon":0},{"id":"2493318424","title":"Shares vs. property: Biggest investment trends of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2493318424","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493318424?lang=en_us&edition=fundamental","pubTime":"2024-12-21 01:30","pubTimestamp":1734715800,"startTime":"0","endTime":"0","summary":"As another year of investing draws to a close, let's review the biggest trends in ASX shares vs. property.  First, let's take a macro view.  At the time of writing, the S&P/ASX 200 Index  is up 5.76% in the year to date . If we add the typical 4% dividend return on top, we get a total estimated return of 9.76%. The two best months of the year for share price gains have been July, when the ASX 200 rose 4.18%, and November, when it lifted 3.38%.  The ASX 200 has reset its all-time record high many times over throughout the year. The latest record was set on 3 December at 8,514.5 points. Meantime, the national home value rose for a 22nd consecutive month in November, according to CoreLogic data. It's now up 5.2% YTD, with total annual returns  tracking at 9.6%.  So, there's not much competition between shares vs. property in terms of overall returns in 2024. Based on current trends, both asset classes will deliver total returns of 9% to 10%. Very satisfactory!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/21/shares-vs-property-biggest-investment-trends-of-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","ZIP.AU","BK7511","BK7501","BHP.AU","BK7507","360.AU","BK7508","XKO.AU","MSB.AU","BK7135","BK7016","BK7093","BK7095","CBA.AU","BK7067","XJO.AU"],"gpt_icon":0},{"id":"2492049122","title":"Galloping to the top of the runners of the week podium is… icetana","url":"https://stock-news.laohu8.com/highlight/detail?id=2492049122","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492049122?lang=en_us&edition=fundamental","pubTime":"2024-12-20 17:04","pubTimestamp":1734685440,"startTime":"0","endTime":"0","summary":"Against a backdrop of jittery global stock markets – the United States Dow Jones has endured a 10-day losing streak – its worst since 1974 - this week’s batch of Runners have still managed to buck the broader trend with solid gains, led by news of an AI deal, a copper mine acquisition and a long-awaited FDA approval.This week’s Bulls N’ Bears ASX Runner of the Week is…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/galloping-to-the-top-of-the-runners-of-the-week-podium-is-icetana-20241220-p5l02x.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["PAT.AU","BK7501","ICE.AU","BK7508","BK7104","BDG.AU","MSB.AU","BK7095","BK7016","BK7067"],"gpt_icon":0},{"id":"2492533154","title":"Why Bellevue Gold, Mesoblast, Pilbara Minerals, and Wesfarmers shares are dropping today","url":"https://stock-news.laohu8.com/highlight/detail?id=2492533154","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492533154?lang=en_us&edition=fundamental","pubTime":"2024-12-20 09:23","pubTimestamp":1734657817,"startTime":"0","endTime":"0","summary":"In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week in a disappointing fashion. At the time of writing, the benchmark index is down a further 1% to 8,086.9 points. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/20/why-bellevue-gold-mesoblast-pilbara-minerals-and-wesfarmers-shares-are-dropping-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","BK7501","BK7508","PLS.AU","BK7095","BK7511","BK4109","MSC","BK7067","BK4575","MTX","WES.AU","BK7104","BK7507","MSB.AU","BK4150","BGL.AU","BK7504","XJO.AU","BK7041","BK7153","MESO"],"gpt_icon":1},{"id":"2492453305","title":"Why the Mesoblast share price is diving 18% after an FDA win","url":"https://stock-news.laohu8.com/highlight/detail?id=2492453305","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492453305?lang=en_us&edition=fundamental","pubTime":"2024-12-20 08:54","pubTimestamp":1734656042,"startTime":"0","endTime":"0","summary":"The Mesoblast Ltd  share price is taking a nosedive today.  Shares in the S&P/ASX 300 Index  clinical-stage biotechnology company closed yesterday trading for $3.05. In late morning trade on Friday, shares are changing hands for $2.49 apiece, down 18.4%. For some context, the ASX 300 is down 0.9% at this same time.  So, why is the Mesoblast share price tumbling just one day after announcing a major US Food and Drug Administration  success?What's going on with the Mesoblast share price today?Well, it looks like investors aren't favouring their sell buttons today despite yesterday's big FDA news, but rather because of it. With no fresh news out from the ASX biotech stock today, we can only conclude that the selling action pressuring the Mesoblast share price is being driven by some healthy profit-taking. You see, investors reacted quite exuberantly to yesterday's news that the FDA had approved the company's Ryoncil  product as the first mesenchymal stromal cell  therapy in the United Sta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/20/why-the-mesoblast-share-price-is-diving-18-after-an-fda-win/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MESO","XKO.AU","BK7501","MSC","BK4150","MSB.AU","BK4575","BK7508","BK7067","BK4139"],"gpt_icon":0},{"id":"2492486534","title":"MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492486534","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492486534?lang=en_us&edition=fundamental","pubTime":"2024-12-20 02:16","pubTimestamp":1734632160,"startTime":"0","endTime":"0","summary":"Mesoblast Limited MESO announced that the FDA has approved Ryoncil  for the treatment of steroid-refractory acute graft versus host disease  in children aged two months and older, including adolescents and teenagers.Following the FDA nod, Ryoncil became the first and only mesenchymal stromal cell therapy to be approved for any indication in the United States.Ryoncil is also the first FDA-approved therapy for pediatric SR-aGvHD, a life-threatening condition with high mortality rates.Shares of MESO were up 40.4% in after-hours trading on Dec. 18. The stock has skyrocketed 456.8% in the year so far against the industry’s decline of 10.5%.The FDA approval was based on data from the phase III study which evaluated Ryoncil for treating children with SR-aGvHD.Data from the same showed that out of 89% of children who had high severity grade C or grade D disease, 70% achieved an overall response by day 28 following treatment with Ryoncil, a measure that predicts survival in aGVHD.A better-ranke","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meso-stock-fda-approves-ryoncil-181600672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE00B4R5TH58.HKD","BK4181","IE0002141913.USD","IE00BJJMRZ35.SGD","HST","BK4532","BK4550","IE0009355771.USD","BK4007","INCY","IE00BFTCPJ56.SGD","SPRO","IE00BJT1NW94.SGD","LU0211331839.USD","NVS","BK4578","BK4139","IE00B2B36J28.USD","BK4588","MESO","BK4218","MSB.AU"],"gpt_icon":0},{"id":"2492044351","title":"Mesoblast Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2492044351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492044351?lang=en_us&edition=fundamental","pubTime":"2024-12-20 01:53","pubTimestamp":1734630780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MESO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 12:53 ET (17:53 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","MESO"],"gpt_icon":0},{"id":"2492179141","title":"U.S.-Listed Shares of Mesoblast up 44% After FDA Approves Cell Therapy for Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492179141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492179141?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:36","pubTimestamp":1734618963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK15V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","BK7508","BK4139","BK7501","BK7067","MSB.AU"],"gpt_icon":0},{"id":"2492285861","title":"BUZZ-Mesoblast gains on FDA nod for graft-versus-host disease cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492285861","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492285861?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:50","pubTimestamp":1734605443,"startTime":"0","endTime":"0","summary":"BUZZ-Mesoblast gains on FDA nod for graft-versus-host disease cell therapy  ** U.S.-listed shares of Australia-based Mesoblast MSB.AX rise 44.2% to $17.67 premarket  ** The U.S. Food and Drug Administration late on Wednesday approved co's cell therapy for treating graft-versus-host disease   ** The therapy, branded as Ryoncil, is approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy ** GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient's cells, mistaking them for an unfamiliar threat** Up to last close, stock rose ~457% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","MSB.AU","BK7501"],"gpt_icon":0},{"id":"2492141398","title":"U.S.-Listed Shares of Mesoblast Surge 49% Premarket After FDA Approves Cell Therapy for Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492141398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492141398?lang=en_us&edition=fundamental","pubTime":"2024-12-19 17:21","pubTimestamp":1734600119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0SX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK4139","MESO","BK7501","BK7067","MSB.AU"],"gpt_icon":0},{"id":"2492194244","title":"Why Champion Iron, EBR Systems, Mesoblast, and Patriot Battery Metals shares are surging today","url":"https://stock-news.laohu8.com/highlight/detail?id=2492194244","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492194244?lang=en_us&edition=fundamental","pubTime":"2024-12-19 10:55","pubTimestamp":1734576924,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is having a very disappointing session following a selloff on Wall Street overnight. In afternoon trade, the benchmark index is down 1.85% to 8,154.7 points. Four ASX s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/19/why-champion-iron-ebr-systems-mesoblast-and-patriot-battery-metals-shares-are-surging-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4575","CIA.AU","XJO.AU","BK4139","MESO","BK7067","MSB.AU","BK7508","IE00B1B80R65.USD","BK7129","BK7007","PMT.AU","MSC","EBR.AU","BK4081","EBR","BK4150","BK7095","PAI","BK7501","PAI.AU"],"gpt_icon":0},{"id":"2492953921","title":"BUZZ-Australia's Mesoblast at 4-yr high on US FDA nod for cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492953921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492953921?lang=en_us&edition=fundamental","pubTime":"2024-12-19 10:12","pubTimestamp":1734574366,"startTime":"0","endTime":"0","summary":"** Shares of Mesoblast    rise as much as 46% to A$2.890, their highest since Dec. 16, 2020   ** Stock posts its biggest intraday percentage rise since April 2   ** Drug developer says U.S. Food and Drug Administration approved co's cell therapy for graft-versus-host disease   ** About 28.1 mln shares change hands, compared with the 30-day average volume of around 6.3 mln   ** Stock up over 825% YTD, including session's move ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7508","XAO.AU","XJO.AU","BK7501","BK7067","XKO.AU"],"gpt_icon":1},{"id":"2492193506","title":"Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492193506","media":"Small Caps","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492193506?lang=en_us&edition=fundamental","pubTime":"2024-12-19 08:59","pubTimestamp":1734569971,"startTime":"0","endTime":"0","summary":"Regenerative medicine company Mesoblast  has been granted US Food and Drug Administration  approval for its Ryoncil therapy to treat children with steroid-refractory acute graft-versus-host disease .The off-the-shelf drug derived from bone marrow has become the first mesenchymal stromal cell therapy on the US market to treat the condition, which can occur after a bone marrow or stem cell transplant and has both a poor prognosis and high mortality rate.Ryoncil will be available from today as an intravenous infusion at US transplant centres and other treating hospitals.Mesoblast chief executive Dr Silviu Itescu welcomed the FDA’s decision.“We are very pleased that the FDA has granted approval of Ryoncil and we are proud of our commitment to the GvHD community in bringing this important new treatment to children and families with no other acceptable options,” he said.“We will continue to work closely with the regulator to obtain approval of our other late-stage products, including Revasco","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/12/Mesoblast-ASX-MSB-Ryoncil-FDA-approval-mesenchymal-stromal-cell.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/12/Mesoblast-ASX-MSB-Ryoncil-FDA-approval-mesenchymal-stromal-cell.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/mesoblast-ryoncil-cell-therapy-fda-approved-acute-graft-versus-host-disease/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4139","BK7508","MSB.AU","MESO","BK7501","BK7067"],"gpt_icon":1},{"id":"2492948162","title":"Mesoblast Receives US FDA Approval for Mesenchymal Stromal Cell Therapy; Shares Hit Four-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2492948162","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492948162?lang=en_us&edition=fundamental","pubTime":"2024-12-19 08:53","pubTimestamp":1734569612,"startTime":"0","endTime":"0","summary":"Mesoblast  received US Food and Drug Administration approval for mesenchymal stromal cell  therapy, Ryoncil, according to a Thursday filing with the Australian bourse.Ryoncil is the only MSC therapy approved in the US for any indication and the only approved therapy for steroid-refractory acute graft-versus-host disease  in children two months and older, the filing said.SR-aGvHD is a stem cell transplant complication where a patient's disease doesn't respond to high-dose steroids.Shares rose nearly 33% in morning trade Thursday and earlier reached their highest since December 2020.Price : $2.63, Change: $+0.65, Percent Change: +32.83%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","AUD","BK4575","LU0345774631.USD","MESO","BK7508","BK4125","BK7501","LU0426417589.USD","LU1043141123.HKD","BK4150","MSC","LU0994945656.USD","BK4139","LU0426412945.USD","LU2238339852.HKD","MSB.AU"],"gpt_icon":1}],"pageSize":16,"totalPage":11,"pageCount":6,"totalSize":161}]}}